Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Lantern Pharma Inc. (LTRN)
|
Add to portfolio |
|
|
|
| Price: |
$7.06
| | Metrics |
| OS: |
10.9
|
M
| |
-30
|
% ROE
|
| Market cap: |
$76.7
|
M
| |
-72
|
% ROIC
|
|
Net cash:
|
$47.9
|
M
| |
$4.41
|
per share
|
|
EV:
|
$28.8
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($15.4)
|
M
| |
|
|
|
EBIT
|
($15.4)
|
M
| |
|
|
| EPS |
($1.31)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 14.6 | 12.7 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 14.8% | | | | |
| Cost of goods sold | 0.0 | 0.0 | 5.4 | 0.0 | 0.0 |
| Gross profit | 14.6 | 12.7 | -5.4 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | | | |
| Research and development | 8.6 | 7.6 | 2.2 | | 0.6 |
| General and administrative | 6.0 | 5.1 | 3.7 | 1.5 | 1.2 |
| EBIT | -14.4 | -12.6 | 0.0 | 1.0 | 0.0 |
| EBIT margin | -99.0% | -99.2% | | | |
| Pre-tax income | -14.3 | -12.4 | -5.9 | -2.4 | -1.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -14.3 | -12.4 | -5.9 | -2.4 | -1.7 |
| Net margin | -97.8% | -97.4% | | | |
| |
| Diluted EPS | ($1.31) | ($1.13) | ($1.37) | ($1.23) | ($0.90) |
| Shares outstanding (diluted) | 10.9 | 10.9 | 4.3 | 2.0 | 1.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|